PI3Kα Pathway Inhibition With Doxorubicin Treatment Results in Distinct Biventricular Atrophy and Remodeling With Right Ventricular Dysfunction

BACKGROUND: Cancer therapies inhibiting PI3Kα (phosphoinositide 3‐kinase‐α)–dependent growth factor signaling, including trastuzumab inhibition of HER2 (Human Epidermal Growth Factor Receptor 2), can cause adverse effects on the heart. Direct inhibition of PI3Kα is now in clinical trials, but the ef...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:J Am Heart Assoc
Autori principali: McLean, Brent A., Patel, Vaibhav B., Zhabyeyev, Pavel, Chen, Xueyi, Basu, Ratnadeep, Wang, Faqi, Shah, Saumya, Vanhaesebroeck, Bart, Oudit, Gavin Y.
Natura: Artigo
Lingua:Inglês
Pubblicazione: John Wiley and Sons Inc. 2019
Soggetti:
Original Research
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC6512135/
https://ncbi.nlm.nih.gov/pubmed/31039672
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1161/JAHA.118.010961
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi